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more recently experienced (similar global score).
However, the age at the time of diagnosis and the level of
incapacity experienced was related (p = 0.015). The
younger the patient is at which psoriasis is diagnosed the
higher the level of handicap is, particularly on the “every-
day” and “leisure” scores.
CONCLUSION: These results highlight the value of
appropriate and relevant psychological and medical 
environment for children suffering from psoriasis.
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Psoriasis is a chronicle disease, which concerns 4.7% of
the French population. Although it does not shorten life
it has major consequences on patients’ daily life because
of the damage to the body image.
OBJECTIVE: The purpose of this study is to report 
preliminary ﬁndings of perceived disability in patients
with psoriasis.
METHOD: SPOT is a longitudinal, prospective, obser-
vational, programme. 2000 patients with mild to moder-
ate psoriasis will be recruited. (1000 Chronic Psoriasis
Patient & 1000 New Psoriasis Patient). The Psoriasis 
Disability Index [PDI] (Finlay AY et al 1987) and the SF
12 are evaluated every 3 months.
RESULTS: The preliminary results concern the analysis
of the ﬁrst 413 PDI scales completed at the inclusion visit.
The mean PDI score of the chronic psoriasis patients
(CPP) (n = 215) was 15,2 (sd 13,2) and the mean PDI
score of the new psoriasis patients (NPP) (n = 198) was
10,4 (sd 11,7) (p < 0.0001). When the sub-group of
retired and housewife patients was analysed there was no
difference in the scores between the CPP and NPP.
However, the sub-group consisting of salaried employees,
unemployed and sick leave patients showed a clear 
difference, mean PDI of CPP 14,4 (n = 149) compared to
NPP mean PDI = 9,7 (n = 158) (p = 0.0003). When all
questionnaires were analysed the “active population” are
less disabled than the “inactive group” (p < 0.05) and this
difference is also seen within the NPP (p < 0.05).
CONCLUSION: This ﬁrst analysis demonstrates the 
disability experienced by CPP and its greater impact on
the “active population”. This study will enable long-term
monitoring of the evolution of patients’ psoriasis and the
perception of patients concerning their management.
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OBJECTIVES: To examine the association between visual
impairment (VI) and functional limitations among the
elderly.
METHODS: Bivariate analyses were used to examine the
above associations. Data used in the analysis was the
Second Supplement on Aging (SOA II), a nationally rep-
resentative sample of the U.S. population aged 70 and
over in 1994. These cohort data of older Americans, col-
lected by the National Center of Health Statistics, are the
most recently released. VI identiﬁed from the data was
categorized into ﬁve forms: cataract, glaucoma, blindness
in one eye, blindness in both eyes, and trouble seeing 
even with glasses. Functional limitations were character-
ized by activities of daily living (ADLs), instrumental
activities of daily living (IADLs), and self-perceived health
status.
RESULTS: VI was found in 37.5% of persons aged 70
and over; among them 10% reported having more than
one form of VI. “Cataract” and “trouble seeing with
glasses”, alone or combined, accounted for approxi-
mately 68% of VI. On average, compared to the visually
unimpaired, the visually impaired group reported a sig-
niﬁcantly higher number of limitations in ADLs (diff =
0.52, P < 0.001) and IADLs (diff = 0.60, P < 0.001). A
signiﬁcantly higher proportion of the visually impaired
ranked their health status as poor (10.7% vs. 5.1%) and
a signiﬁcantly lower proportion reported “excellent”
(9.4% vs. 14.8%). Among the ﬁve forms of VI, the
average number of limitations in ADLs and IADLs were
highest among persons with blindness in both eyes (2.36
and 3.67, respectively), and were lowest in the glaucoma
group (0.86 and 0.89, respectively).
CONCLUSIONS: A positive and tangible association
existed between VI and more limited physical function-
ing as measured by ADLs and IADLs, and poorer self-
perceived health. Among the ﬁve forms of visual problems
examined, the most detrimental outcomes were found in
persons with blindness in both eyes.
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OBJECTIVE: Assess the antihistamine utilization and
associated costs in patients with atopic dermatitis (AD).
